Argenica Therapeutics (ASX:AGN), a clinical-stage biotechnology company developing neuroprotective therapeutics, has disclosed that the US Food and Drug Administration has maintained a clinical hold on its Investigational New Drug application for xaranetide in acute ischaemic stroke, requesting an additional rat neurotoxicity study before clinical dosing in the United States can proceed.
Key Points
- The FDA has maintained the clinical hold on Argenica's IND for xaranetide, advising that removal is not warranted pending additional information.
- The FDA has requested a GLP non-clinical neurotoxicity study assessing whether xaranetide forms toxic Olney lesions in rats, to be completed before further human dosing under the IND.
- The FDA has revised downward the permitted clinical plasma exposure limit, below the doses included in the company's proposed trial design submitted in September 2026.
- The company has identified what it describes as substantially greater variability in the data relied upon by the FDA for the revised exposure limit, and does not agree with the FDA's position.
- Argenica plans to request a Type A meeting with the FDA and will continue to progress regulatory submissions in other jurisdictions.
FDA Clinical Hold Review and Neurotoxicity Study Requirement
The FDA completed its review of Argenica's clinical hold complete response, which was submitted on 23 September 2026, addressing matters raised in the FDA's August 2025 letter. The FDA's feedback maintaining the hold was provided over four weeks after the mandatory 30-day deadline. The regulator has requested a GLP non-clinical neurotoxicity study to assess whether xaranetide produces Olney lesions in rats. The FDA noted that Olney lesions can arise in rats given high-affinity NMDA channel blockers producing sustained, complete receptor blockade. No microscopic damage to the brain has been identified in non-clinical animal studies of xaranetide conducted to date, according to the filing. The FDA has offered to review the study protocol in advance.
Disputed Clinical Exposure Limit Revision
The FDA has stated it requires a ten-fold margin to the rat exposure at the no-effect level for dosing in the Phase 2b trial, and has revised downward the permitted plasma exposure limit derived from non-GLP toxicokinetic data in a single rat cohort within a specific non-clinical study. The revised limit sits below the doses included in the trial design submitted in September 2026, meaning any future US study would need to commence at a lower dose with a clear plan for dose escalation. The company said a preliminary review identified substantially greater variability in the data being relied upon by the FDA, and that the revised limit does not align with previously provided GLP toxicokinetic data.
Next Steps Including Type A Meeting Request and Other Jurisdictions
Argenica stated it will work with its non-clinical contract research organisation to verify the variability in the data and intends to seek further discussion with the FDA regarding the basis for the revised exposure limit. The company plans to request a Type A meeting with the FDA to discuss the outstanding matters further. Argenica also disclosed it will continue to progress regulatory submissions in other jurisdictions while seeking resolution of the FDA matters. The company said it will seek quotes from clinical research organisations to obtain an indication of the investment required for the Olney lesion neurotoxicity study.





Please wait processing your request...